NCT03722498 2023-07-11
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Phase 2 Withdrawn
Clinical Trials
14 trialsNCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT02129322 2021-02-15
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Phase 2 Withdrawn
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT02288507 2019-11-08
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Withdrawn
NCT03780634 2019-05-06
HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT02908165 2018-01-10
Randomized Phase II Trial of Chemoembolization and Sorafenib
Yale University
Phase 2 Withdrawn
NCT02406508 2017-12-18
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Delcath Systems Inc.
Phase 2 Withdrawn
NCT01335074 2016-11-15
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Philipps University Marburg
Phase 1/2 Withdrawn
NCT01801163 2015-04-16
A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Indiana University
Phase 1 Withdrawn
NCT00808145 2014-10-22
Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)
Lahey Clinic
Phase 2 Withdrawn
NCT01618253 2013-09-05
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Medical College of Wisconsin
Phase 1 Withdrawn
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT01245582 2011-11-09
SECOX
Sanofi
Phase 3 Withdrawn